Primary central nervous system lymphoma epidemiology and demographics

Primary central nervous system lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Primary Central Nervous System Lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Primary central nervous system lymphoma epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Primary central nervous system lymphoma epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Primary central nervous system lymphoma epidemiology and demographics
CDC on Primary central nervous system lymphoma epidemiology and demographics
Primary central nervous system lymphoma epidemiology and demographics in the news
Blogs on Primary central nervous system lymphoma epidemiology and demographics
Directions to Hospitals Treating Primary central nervous system lymphoma
Risk calculators and risk factors for Primary central nervous system lymphoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Incidence

The incidence of PCNSL in the immunocompetent population has been reported to have increased more than 10-fold from 2.5 cases to 30 cases per 10 million population. The cause for the increase in incidence of this disease in the immunocompetent population is unknown.

Age

Primary central nervous system lymphoma does not have predilections for any age group. In the immunocompetent population, PCNSL typically affects older patients in their 50's and 60's.